Skip to main content
All lobbying filings

TODD STRATEGY GROUP

Lobbying for ALKERMES, INC. · ​Pharmaceutical manufacturing and biopharmaceutical company.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $60,000.00 income · posted Apr 20, 2026

Official filing document

 Lobbying activity 1
Health Issues

Prescription drug pricing, including MDRP. Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. Medicaid drug rebate program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem